Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Sanofi’s Candidate Failed, Merck’s Zinplava Never Gained Traction
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
